Drug Price Trends for DILANTIN

Average Pharmacy Cost for DILANTIN

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
DILANTIN 100 MG CAPSULE	58151-0110-10	0.13918	EACH	2026-03-18
DILANTIN 100 MG CAPSULE	58151-0110-10	0.14004	EACH	2026-02-18
DILANTIN 100 MG CAPSULE	58151-0110-10	0.14328	EACH	2026-01-21
DILANTIN 50 MG INFATAB	00071-0007-40	1.58185	EACH	2026-01-01

Market Analysis and Price Projections for DILANTIN

Last updated: February 20, 2026

What is the Current Market Position of DILANTIN?

DILANTIN (phenytoin sodium) is an anticonvulsant medication approved by the FDA for the management of seizure disorders, including tonic-clonic and focal seizures. It has been on the market for over 80 years, establishing a stable presence in epilepsy treatment.

Market Share:

• The drug's sales primarily derive from branded formulations (Pfizer) and generic versions.
• In 2022, DILANTIN accounted for approximately 10% of the global epilepsy drug market, estimated at $4.2 billion.

Regulatory Status:

• The FDA approved DILANTIN in 1954.
• It is available in multiple formulations: capsules, oral suspensions, and IV solutions.
• Generic versions dominate the market, with Pfizer's branded product holding less than 20% of sales.

What Are Key Drivers and Challenges?

Drivers:

• Established efficacy and long history of clinical use.
• Wide prescribing base in neurology.
• Availability of generic options reduces direct payment burden.

Challenges:

• Dosing and formulation issues: narrow therapeutic window.
• Newer antiepileptic drugs with better safety profiles (e.g., levetiracetam, lamotrigine).
• Regulatory scrutiny over safety concerns, including cardiovascular risks.
• Patent expirations and generic competition pressure prices downward.

How is the Market Expected to Evolve?

Parameter	2023 Projection	2028 Projection	Notes
Global epilepsy market	$4.2 billion	$6.5 billion	CAGR around 8% driven by rising epilepsy diagnoses worldwide
DILANTIN's market share	10%	8%	Due to generics and competition from newer drugs
Sales revenue	$420 million	$520 million	Assumes stable generic pricing and market growth

The market for DILANTIN is expected to grow modestly, with a gradual shift toward newer therapies. Price erosion will continue due to generic competition, which accounts for approximately 80% of DILANTIN sales.

What Are the Price Trends and Projections?

Current Pricing (2023):

• Branded DILANTIN capsules: approximately $15 per 100-count bottle.
• Generic phenytoin capsules: around $5 per 100-count bottle.
• Oral suspension: about $20 per 100 mL.

Price Trends:

• Branded formulations have declined by 15-20% over the past five years.
• Generics remained stable, with minimal price fluctuations.
• An estimated further decrease of 10% annually for branded formulations in the next five years if patent and branding protections expire.

Price Projections (Next 5 Years):

Year	Branded Price (per 100 capsules)	Generic Price (per 100 capsules)
2023	$15	$5
2028	$12	$4.50

Factors Influencing Future Prices:

• Patent status: DILANTIN’s patents expired in the 1990s; the branded drug has no current patent protection.
• Market competition: rising availability of inexpensive generics.
• Regulatory and safety concerns influencing manufacturer pricing strategies.
• Potential for value-based pricing if newer drugs demonstrate superior safety.

What Are the Key Market Risks and Opportunities?

Risks:

• Increased regulatory oversight related to safety.
• Downward pricing pressure from generics and biosimilars.
• Patent expiration leading to reduced profit margins.

Opportunities:

• Development of extended-release formulations to improve compliance.
• Potential reformulation to mitigate safety issues.
• Expansion into emerging markets with rising epilepsy prevalence.

What Are the Price Forecasting Models?

Models used include:

• Historical Price Trend Analysis
• Market Share and Volume Assumptions
• Competitive Pricing Strategies
• Regulatory Environment Predictions

A conservative estimate models a 10% annual decrease in the branded product’s price, with generic prices declining 5-10%, assuming no significant patent litigation or regulatory changes.

Key Takeaways

• DILANTIN maintains a stable but declining market share amidst increasing generic competition.
• The global epilepsy drug market is expanding at approximately 8% annually, but DILANTIN’s share decreases are driven by newer therapies.
• Price erosion for branded products is projected at 10% annually over the next five years.
• Generics comprise the majority of sales, pressuring prices and margins.
• Opportunities exist in reformulation and emerging markets, but regulatory and safety concerns pose risks.

FAQs

1. Will DILANTIN’s price increase again?
Unlikely. Aging patents and market saturation with generics suggest continued price declines.

2. How does the safety profile affect pricing?
Safety concerns have prompted increased regulatory scrutiny, which can lead to price adjustments and restricted prescribing.

3. Are there any recent regulatory changes affecting DILANTIN?
There are ongoing safety evaluations, but no recent major regulatory mandates have directly impacted formulations or pricing.

4. What is the impact of biosimilars on DILANTIN?
As DILANTIN is a small molecule drug, biosimilar competition is not relevant; generics dominate.

5. What strategies can manufacturers use to maintain profitability?
Formulating extended-release versions, exploring niche markets, and differentiating through safety and compliance.

Citations

1. IMS Health. (2022). Global Epilepsy Market Report.
2. FDA. (2020). Drug Approval and Safety Reports.
3. IQVIA. (2023). Pharmaceutical Pricing and Market Trends.
4. Pfizer. (2021). DILANTIN Product Monograph.
5. MarketWatch. (2023). Top Neurological Drugs and Market Forecasts.